Efficacy and Safety of Auricular Acupressure for Insomnia in Patients With Functional Dyspepsia: A Randomized Controlled Trial.

Am J GastroenterolDec 10, 2025 (epub)
Clinical ResearchGastroenterologyPsychiatryOpen access

Meng-Yuan Shen, Ze-Jiong Li, Rong Zhou et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated auricular acupressure (AA) for insomnia in patients with functional dyspepsia (FD), comparing treatment at the ear concha with sham acupressure at the earlobe. Eighty-two participants were randomized equally between groups and treated over 2 weeks. At week 2, the response rate—defined as at least a 50% reduction in Pittsburgh Sleep Quality Index score—was 53.7% with AA versus 29.3% with sham (95% confidence interval -35.6 to -13.2, P < 0.001). The reported benefit persisted during the 8-week posttreatment follow-up; adverse events were mild and comparable.

Key findings

  • At week 2, response rates were 53.7% with AA and 29.3% with sham AA (95% confidence interval -35.6 to -13.2, P < 0.001).
  • The efficacy of AA was sustained during the 8-week posttreatment follow-up.
  • Adverse events were mild and comparable between groups (P = 0.53).

Why it matters

Insomnia commonly affects people with FD, and this trial found a higher short-term response rate with AA than with sham treatment, with benefit reported through follow-up. The findings add randomized evidence on a nonpharmacological approach in this population, while the reported outcomes and follow-up do not establish broader or longer-term effects.

What to keep in mind

The trial included 82 participants, and follow-up after treatment was limited to 8 weeks.

Source

Published in Am J Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.